Pomalidomide, Cyclophosphamide and Dexamethasone (PCd): Outcomes in Patients With Double- or Triple-Refractory Multiple Myeloma. - Hidalgo-Soto M; Rodríguez-Lobato LG; Motlló Borrella C; Sánchez Cayuela Á; Lopez Pardo J; Rosiñol L; Cibeira MT; García-Guiñon A; Tolosa-Ridao C; Carro Arostegui I; Sureda A; Herranz MJ; et al. (European journal of haematology, 2026)